GERN
Geron Corp.
Halal Rating :
Last Price
$2.89
Last updated:
Market Cap
-
7D Change
-3.02%
1 Year Change
41.67%
Company Overview
Industries
Exchange
Next Earnings Date
Geron Corporation is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics for hematologic malignancies. Their lead product candidate is imetelstat, a telomerase inhibitor that is being developed for the treatment of hematologic malignancies including lower risk myelodysplastic syndromes (MDS) and refractory myelofibrosis (MF).
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $28.27m | $59.53m | - | $3.05m | 0.00% | 5.12% |
| June 30, 2024 | $882000.0 | $73.53m | - | $3.32m | 0.00% | 4.51% |
Company Impact
Help us evaluate Geron Corp.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.